Should we launch ourselves in Europe or consider partnering/outlicensing, and how do we decide?

Access decades of experience

Launch Path Decision

Explore how biopharma leaders weigh the pros and cons of launching independently versus partnering in Europe.

Investment vs. Return

Understand what shapes the financial calculus behind building a European presence or sharing the load.

Market Fit Factors

See which product and pipeline traits make a self-launch realistic—or why a partner might add more value.

Strategic Evolution

Discover how hybrid and staged models let companies balance control, speed, and long-term ambition.